Identification of anticancer drugs to radiosensitise <i>BRAF</i>-wild-type and mutant colorectal cancer

Identification of anticancer drugs to radiosensitise <i>BRAF</i>-wild-type and mutant colorectal cancer

<b>Objective</b> Patients with <i>BRAF</i>-mutant colorectal cancer (CRC) have a poor prognosis. Molecular status is not currently used to select which drug to use in combination with radiotherapy. Our aim was to identify drugs that radiosensitise CRC cells with known <i&g...

Full description

Bibliographic Details
Main Authors: Rebecca Carter, Azadeh Cheraghchi-Bashi, Adam Westhorpe, Sheng Yu, Yasmin Shanneik, Elena Seraia, Djamila Ouaret, Yasuhiro Inoue, Catherine Koch, Jenny Wilding, Daniel Ebner, Anderson J. Ryan, Francesca M. Buffa, Ricky A. Sharma
Format: Article
Language:English
Published: China Anti-Cancer Association 2019-06-01
Series:Cancer Biology & Medicine
Subjects:
Radiosensitizer
colorectal cancer
PARP inhibitor
radiotherapy
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1419

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1419

Similar Items